Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**18f-florastamin** is an injectable radiopharmaceutical diagnostic agent labeled with fluorine-18; it targets the prostate-specific membrane antigen (PSMA) for *PET/CT imaging of prostate cancer*. The active molecule, florastamin, binds to PSMA-expressing tumor cells, and the F-18 isotope allows visualization through positron emission tomography. Its main utility is in detecting primary and metastatic prostate lesions, especially small lymph nodes and active osseous metastases that may evade conventional anatomical criteria. Clinical trials indicate high lesion detectability, superior tumor-to-background ratio, and facilitation of personalized procedures such as irreversible electroporation. It is also characterized by facile radiochemistry and favorable pharmacokinetics[1][2][3][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18f-florastamin.